Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$649K Sell
12,781
-48,993
-79% -$2.29M 0.01% 266
2025
Q4
$1.82M Buy
61,774
+16,865
+38% +$458K 0.04% 159
2025
Q3
$1.16M Sell
44,909
-66,527
-60% -$1.86M 0.01% 438
2025
Q2
$3.07M Buy
111,436
+99,641
+845% +$2.62M 0.03% 214
2025
Q1
$334K Sell
11,795
-2,779
-19% -$98.6K ﹤0.01% 462
2024
Q4
$606K Buy
14,574
+799
+6% +$38.2K 0.01% 432
2024
Q3
$921K Sell
13,775
-6,016
-30% -$552K 0.02% 361
2024
Q2
$2.35M Buy
19,791
+989
+5% +$125K 0.04% 190
2024
Q1
$2M Buy
18,802
+5,145
+38% +$519K 0.04% 247
2023
Q4
$1.36M Buy
13,657
+55
+0.4% +$4.63K 0.02% 302
2023
Q3
$1.4M Buy
13,602
+8
+0.1% +$892 0.02% 281
2023
Q2
$1.65M Sell
13,594
-1,347
-9% -$180K 0.03% 231
2023
Q1
$2.29M Sell
14,941
-2,579
-15% -$425K 0.05% 192
2022
Q4
$3.15M Buy
17,520
+12,486
+248% +$2.04M 0.08% 157
2022
Q3
$595K Buy
5,034
+1,811
+56% +$275K 0.02% 351
2022
Q2
$460K Buy
+3,223
New +$461K 0.01% 323
2022
Q1
Sell
-769
Closed -$195K 464
2021
Q4
$195K Sell
769
-16,566
-96% -$4.84M 0.01% 367
2021
Q3
$6.67M Buy
+17,335
New +$6.39M 0.19% 92

Other funds holding MRNA

Ossiam's MRNA Position: Q1 2026 in Review

Ossiam reduced its Moderna (MRNA) stake by 79% in Q1 2026, selling an estimated $2.29M and leaving 12,781 shares worth $649K. The position accounts for 0.01% of the portfolio, ranked #266.

Ossiam first reported a position in MRNA in Q3 2021 and has held it in 18 quarters since. The position peaked at $6.67M in Q3 2021. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Ossiam held 12,781 shares of Moderna worth $649K as of Q1 2026.
  • Ossiam sold 48,993 Moderna shares in Q1 2026, an estimated $2.29M.
  • Moderna made up 0.01% of Ossiam's portfolio in Q1 2026, its #266 holding.
  • Ossiam first reported a position in Moderna in Q3 2021 and has held it in 18 quarters since.
  • Ossiam's Moderna position peaked at $6.67M in Q3 2021.
  • 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Ossiam's 13F filing for Q1 2026, filed 14 May 2026.